Seaport Research analyst Sonny Randhawa lowered the firm’s price target on Trulieve Cannabis (TCNNF) to $21 from $24 and keeps a Buy rating on the shares. The company has a dominant position in the Florida medical market and a strong balance sheet that should create shareholder value for years, the analyst tells investors
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCNNF:
- Trulieve Cannabis upgraded to Speculative Buy from Market Perform at Cormark
- Trulieve Cannabis Reports Strong 2024 Financial Results
- Trulieve Cannabis Reports Strong Earnings Amidst Challenges
- Trulieve Launches Onward: A Premium THC Beverage Line
- Trulieve Expands Ohio Presence with New Columbus Dispensary
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue